Zhejiang Ausun Pharmaceutical603229.SHValuation Analysis

As of Oct 19, 2026, Zhejiang Ausun Pharmaceutical (603229.SH) trades at a P/E of 78.00x, P/B of 2.64x, P/S of 6.72x, and a dividend yield of 0.84%.
Longitudinal percentile comparison: P/E sits at the 82nd percentile over the trailing 10Y window (vs. 94th percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/S sits at the 12th percentile over the trailing 10Y window (vs. 37th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 76th percentile within its industry and the 74th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.64%, ranking at the 99th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 77.7 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 1.64% total shareholder yield, 0.84% is paid out as dividends and roughly 0.80% is implied to come from buybacks — both channels are meaningfully in play. Zhejiang Ausun Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.